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Background to the debate: The financial ties between
doctors and drug companies have come under intense
scrutiny in recent years. Some commentators—such as
Marcia Angell, former editor-in-chief of the New England
Journal of Medicine—argue that the mission of doctors is
fundamentally different to the mission of drug companies
and that the ties between them should be completely cut.
‘‘Drug companies are investor owned businesses with a
responsibility to maximise profits for their shareholders,’’
says Angell [1]. ‘‘That is quite different from the mission of
the medical profession, which is to provide the best care
possible for patients.’’ Other commentators have argued
that clinicians and drug companies do have some shared
goals in aiming to maximize human health. In this debate,
Emma D’Arcy, co-founder of a social networking site that
facilitates interactions between doctors and drug compa-
nies, argues that it would be valuable to the public if we
could establish ‘‘authentic alliances’’ between these
professionals. But journalist Ray Moynihan argues that
such alliances are prone to the corrupting influence of
pharmaceutical industry money, and that disentangle-
ment is a healthier alternative.
Emma D’Arcy’s Viewpoint: We Should Embrace a
New Era of Engagement and Shared Aspirations
The relationship between doctors and drug companies is the
subject of intense scrutiny—there is widespread skepticism about
the intent of industry and concern for the vulnerability of doctors
in the relationship. Unfortunately, the debate on how to move this
relationship forward has become polarized: industry argues that
collaboration with physicians is essential to scientific advancement,
but at the same time many doctors are pledging to cut all their ties
to drug companies (see, for example, the No Free Lunch pledge at
http://www.nofreelunch.org/pledge.htm).
But there is surely one thing we can all agree upon: both the
pharmaceutical industry and health care professionals must focus
on the goal of improving health. We seem to have lost sight of the
shared aspirations between medical and pharmaceutical profes-
sionals. It is in everyone’s interest that medicines are safe and
effective. It is not credible to imply that health care professionals
are easy victims to an industry that readily fools them with its
marketing tactics. Many physician leaders find it condescending to
be considered so malleable to ‘‘marketing exercises,’’ and it is
offensive to suggest they cannot conduct an ethical exchange with
industry. Despite strong differences between doctors and drug
companies, now is surely a critical time to determine how to
establish and nourish authentic alliances between these profes-
sionals.
The media prefer to publish stories about unsafe drugs, doctors
who succumb to financial incentives, and sensationalized accounts
of drug companies suppressing unfavorable trial data. These news
stories fuel public fear that interactions with industry are eroding
physicians’ professionalism. Yet there are many examples where
industry has acted purely in the public interest with no expectation
of financial rewards. For example, many drug companies readily
award grants for scientific meetings that are important to the
research community without expectation that promotional
information will be included. In addition, the pharmaceutical
industry is an extremely important source of funding for
continuing medical education—35% of the estimated US$9–
US$14 billion that industry spends each year on pharmaceutical
marketing goes towards educational support [2]. If pharma-
sponsored education is no longer allowed, we may witness
tomorrow’s doctors practicing yesterday’s medicine.
It is in industry’s best interests to develop drugs that help health
care professionals excel in treating their patients. Each drug
company must achieve such drug development within a highly
regulated environment where governments, trade associations,
professional societies, and individual company codes of practice
apply to protect scientific integrity. Medical innovation may be
hindered if we further limit interactions. Medical professionals and
industry researchers may find it equally frustrating if restrictions
on interactions limit their professional aspirations.
The pharmaceutical industry is held responsible for the rising
costs of health care. But surely industry deserves to be rewarded
for the financial risks they have taken to develop new prescription
drugs. It is easy to forget that products developed by industry have
consistently improved human health for three decades. Industry
capitalizes on our desire to live longer, healthier lives; it is arguably
a victim of its own success in meeting our desires. When industry
and physicians collaborate, the most likely result is expediency in
producing new treatments. The first step to recover the value of
such collaboration is to accept that both parties must assume
accountability for the transparency and outcomes of their
interactions.
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healthier relationships between doctors and drug companies
without having to introduce yet more stringent regulations.
Teaching Physicians ‘‘Promotional Literacy’’
Medical professionals should be taught to distinguish between
sound clinical information and promotional materials. They
should be able to assess, for example, the quality of a clinical
trial and whether the outcome could have been unduly influenced
by commercial forces.
Encouraging the Adoption of ‘‘Good Relationship
Practice’’
Health and pharmaceutical professionals should both follow a
set of rules to guide healthy interactions. This could take the form
of three simple questions—an ‘‘everyday credo’’ to ask oneself
before attempting to engage in a new physician–pharma alliance
(see Box 1).
Ensuring Transparency from Both Parties, While Allowing
Healthy Networking
Both parties must be transparent about combining research,
clinical, and educational endeavors within a framework of
professional networking. Such networking could be assisted by
online professional networking facilities such as http://www.
myphid.com/ and http://www.medcrowd.com/.
Responsible leadership is no longer about influencing opinion
but is instead about aligning aspirations and realizing ambitions.
Doctors champion patient needs, and pharma requires a positive
presence in health care committed to addressing these needs. Both
groups want to make necessary moves to improve interactions.
Embracing a new era of engagement and acknowledging the
positive aspects of aligning will move this debate from rhetoric to
reality.
Ray Moynihan’s Viewpoint: Disentanglement Will
Deliver a Healthier Relationship between Doctors
and Drug Companies
The idea of establishing and nourishing ‘‘authentic alliances’’
between doctors and drug companies, in order to embrace a ‘‘new
era of engagement,’’ sounds extremely enticing. Surely, as Emma
D’Arcy eloquently argues, it is time to put behind us all this
tiresome talk of physicians being in bed with pharmaceutical
companies, and focus instead on the ‘‘shared aspirations’’ to
improve human health. Sadly, her Viewpoint is more beguiling
than revealing, drawing on the marketing catchphrases of her Web
site (http://www.myphid.com/) rather than addressing the crude
financial question at the heart of this debate: who pays for the
pizza?
Healthy new relationships can only be built by a medical
profession that disentangles itself from the corrupting influence of
the billions it accepts annually from the marketing budgets of big
pharmaceutical companies. Whether it’s the free pizza at grand
rounds, the inflated honoraria that ‘‘key opinion leaders’’ take for
promoting the latest pills, or the prestigious contracts for
sponsored ‘‘scientific research’’ often driven more by shareholder
interest rather than public need, ending such entanglement is
surely one way to deliver a healthier relationship between doctors
and drug companies.
Certainly given the high profile of Senator Charles Grassley’s
investigations (he recently urged the American Psychiatric
Association to disclose its drug industry ties [3]), and Pfizer’s
recent announcement that it was considering disclosing payments
of at least $US500/year to doctors [4], you could be forgiven for
thinking we are living in a new era of transparency. A few short
years ago such basic transparency mechanisms would have been
seen as unworkable and unnecessary. But disclosing ties that can
distort prescribing behavior, such as those shown in a study by
Ashley Wazana [5], is not the same as disentangling them.
I worry that Emma D’Arcy’s Viewpoint may in fact be part of a
new era of public relations rhetoric designed to persuade
physicians and policy makers that there is such a thing as a free
lunch, and that cutting ties with drug companies is a risky business.
I suspect too that we are likely to hear a lot more noise about how
doctors and their associations can continue to accept pharmaceu-
tical industry money without it perverting their professional
practice. And a lot of doctors will be receptive to that rhetoric
because there is a lot more at stake here than giving up access to
free pens. Drug company largesse still lubricates the lifestyles of
many physicians, funding the fancy meals and the five-star hotel
rooms, sponsoring the medical education and the scientific
conferences, facilitating the prestigious research and the all-
important publications.
A key obstacle to cleaning up this mess is that many of the so-
called ‘‘key opinion leaders’’ who ‘‘educate’’ their peers at
seminars and conferences are living a lie: pretending they can
simultaneously serve the private interests of their sponsors and the
public interest that is supposed to flow from their academic and
professional responsibilities. As the recent Josiah Macy, Jr.
Foundation report observed, the responsibilities of doctors and
drug companies are ‘‘fundamentally incompatible’’ [6] and there
should be a comprehensive ban on all industry funding of
continuing medical education.
Doctors gaining mandated professional credits by listening to
company-sponsored speakers at company-sponsored events orga-
nized by company-sponsored associations is an obscene perversion
of education that is an embarrassment to all involved. To claim
with a straight face that drug and device makers sponsor such
‘‘education’’ as some kind of selfless service, or that medical
practice will suffer if doctors are educated in independently funded
forums, is as bizarre as it is unbelievable.
Similarly, just as doctors are starting to seek out educational
activities genuinely free of drug company funding and influence, so
too, more prescribers are starting to politely decline the
opportunity to be fed and ‘‘informed’’ by drug company
Box 1. Three Questions That Should Be Asked
Before Engaging in a Physician–Pharma Alliance
N Does this interaction, or series of interactions, encourage
scientific exchange of information or lead to an
enhanced skill that will ultimately benefit the care of
people living with disease and/or enhance the knowl-
edge of those aspiring to help people to overcome,
manage, or better understand a medical condition?
N Does this interaction require the individuals to have a
good knowledge of the drug development process and/
or an understanding about how industry uses promo-
tional messaging of clinical data?
N Is there any possibility that this interaction could be
viewed as an inappropriate activity that could damage
the perception of any of the participants’ intentions and
integrity to engage in a positive collaboration that
furthers medical scientific understanding?
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Association’s ‘‘PharmFree’’ strategy has advocated the severing of
many of these financial ties, prefiguring a future where far fewer
doctors will be prescribing under the influence of industry [7].
In my view the nascent moves towards disentanglement
witnessed in recent years—in hospitals, universities, and profes-
sional associations—will only intensify, as new disclosure regimes
attract even more public attention to these unhealthy relationships.
Visits by ‘‘sexy’’ sales representatives, drug-sponsored continuing
medical education, or scientific conferences in exotic locations
could very quickly become laughable images of a bygone era.
The question of how to build relationships around genuine
research is more complex. As the BMJ editor Fiona Godlee said in
a recent special issue devoted to this topic, doctors should engage
only in research and clinical collaborations that are ‘‘transparent
and unbiased in their design and reporting’’ [8]. But they must
also say no, she argued, to all gifts and hospitality, and should
refuse to be ghost authors, decline any roles as paid opinion
leaders, and fund their own education and information.
One of the basic rules of journalism is follow the money. The
problem with Emma D’Arcy’s Viewpoint is its lack of clarity on
the appropriateness of the myriad flows of money between doctors
and drug companies. Similarly, despite the ‘‘transparency’’
rhetoric, it is not immediately clear who is paying the bills for
her own social networking Web site, which states: ‘‘welcome to a
new era and environment that recognises and rewards scientific
collaborations of merit.’’ A detailed list of sponsors and
descriptions of what the contracts with those sponsors involve
would be very welcome.
Emma D’Arcy’s Response to Ray Moynihan’s
Viewpoint
While it is a pleasure to be described by Ray Moynihan as
eloquent, it is a shame that this debate defaults to cynical sniping. I
am not a secret PR strategist for industry. Nor am I enjoying great
commercial success in trying to create an environment where
unproductive mud-slinging stops and all parties seek appropriate
ways to work together.
Moynihan asks for a ‘‘detailed list of sponsors’’ of myPHID, and
for Expert Sessions these are available online at www.myPHID.
com. The aspirations of this Web site reflect what lies at the heart
of this debate—behaving differently, behaving better. That’s not a
marketing slogan—it’s common sense.
This new attitude requires all stakeholders to behave with
respect as befits professionals. The pioneers from both the medical
profession and the pharmaceutical industry featured on the Web
site, for example, are highly respected and praised for their
integrity. Doctors on myPHID often recommend members of the
pharmaceutical industry, and vice versa, as beacons of scientific
sincerity determined to improve patient outcomes. There is no
‘‘sexy’’ puppeteer manipulating their engagements—individual
members of myPHID are simply choosing to work with others who
excel in their chosen field. This cooperative dignity must be a
fundamental working credo in seeking solutions to the challenges
of interactions between the medical community and the
pharmaceutical industry. Accordingly, I do not dictate the outputs
of myPHID—the community that uses it to increase transparency
and establish better alignments dictates them. Social networking
methodologies lead to ‘‘user-generated’’ content and more equal
conversations. Such conversations elevate the debate about
physician–drug company interactions above the ‘‘victim–persecu-
tor–rescuer’’ drama that has been given so much airtime and that
is based on questionable evidence of any harm from such
interactions. The ‘‘facts’’ cited by those who criticize physician–
drug company relationships provide little substantiation that so-
called ‘‘entanglements’’ are unhealthy. And thanks to ‘‘key opinion
leaders,’’ industry-funded medical innovations reach patients.
As for Moynihan’s call for a ‘‘comprehensive ban on all industry
funding of continuing medical education,’’ this suggests that all
industry professionals are devious and that all medical profession-
als are inducible. The issue at stake here is not whether industry
funding of education is a selfless act—what matters is the quality of
the educational content. If there truly is evidence that all
company-sponsored education is, as Moynihan suggests, ‘‘an
obscene perversion of education,’’ then let’s see it. The myPHID
community would want to see this evidence and use it to make
changes.
Moynihan and I do agree on one thing—the lack of clarity in
the relationships between doctors and drug companies needs to be
addressed. But I believe that there will be no clear route forward if
we simply continue to perpetuate the false idea that ‘‘working with
pharma is bad.’’ Medical and pharmaceutical professionals alike
should be applauded for committing time and energy to
collaborative projects such as those that myPHID is trying to
coordinate. If Ray Moynihan would like to sponsor an Expert
Session on myPHID that truly opens this debate and allows
articulation of all viewpoints, we would certainly be delighted to
accept his sponsorship and make it accessible to all.
Ray Moynihan’s Response to Emma D’Arcy
Anyone genuinely interested in evidence about the dangers of
entanglement need go no further than the Web site of the
nonprofit group Healthy Skepticism (http://www.healthyskepti-
cism.org/), which boasts a wealth of peer-reviewed data suggesting
money does in fact buy influence. For example, one systematic
review found that ‘‘studies sponsored by pharmaceutical compa-
nies were more likely to have outcomes favouring the sponsor than
were studies with other sponsors,’’ pointing to a ‘‘systematic bias’’
in funded research [9].
Similarly, while ‘‘key opinion leaders’’ enthusiastically help
medical innovations reach patients, the question is whether that
enthusiasm always arises from dispassionate analysis of data, or
whether it might be related to the promise of on-going lucrative
consultancies. As long-time drug company insider Kimberley
Elliott put it recently: ‘‘Key opinion leaders were salespeople for
us, and we would routinely measure the return on our investment,
by tracking prescriptions before and after their presentations. If
that speaker didn’t make the impact the company was looking for,
then you wouldn’t invite them back’’ [10].
Influence is obviously often far less crude than this, though a
recent investigation suggests it is pervasive nonetheless, even
affecting fully accredited educational events [11]. A popular
provider of education for Australian doctors was for several years
offering sponsors the explicit chance to help determine topics and
speakers for seminars, sold to participants as ‘‘independent of
industry influence’’ [11]. More importantly, industry representa-
tives confirmed that it’s not unusual for sponsors to suggest
speakers for these educational events. Given this unhealthy
influence of drug companies upon medical education, some
journal editors believe the time has come for doctors to pay for
their own education. Similarly, the authors of the 2008 Josiah
Macy, Jr. Foundation report called for the ‘‘comprehensive ban’’
reported on in my Viewpoint above, suggesting that educational
providers ‘‘should not accept any commercial support from
pharmaceutical or medical device companies,’’ whether directly
or indirectly [6].
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vulnerable as anyone else to the ‘‘food, flattery, and friendship’’
that comes with subsidized seminars, free trips, and fancy hotel
rooms. Which is why getting out of bed with drug companies is not
going to be easy. I know from bitter experience. After the
Association of Health Care Journalists introduced its 2004 policy
of not accepting for-profit health care company sponsorship [12],
the quality of accommodation at its conferences seemed to decline
somewhat. I remember arriving at a North Carolina conference,
after a very long flight from Australia, and being forced to slum it
in a single bed, in a shared room with a fellow writer who,
unfortunately, had a bit of a snore. The conference, nevertheless,
was a great success.
In 2004, the newly launched PLoS Medicine announced it would
be free of drug company advertising, and would not profit from
the business of exclusive reprint sales to the pharmaceutical
industry. The editors adopted this position in order to ’’break the
cycle of dependency’’ between the medical profession and the
pharmaceutical industry, and to create a ‘‘healthy’’ journal, where
debates like this one take place in the sunshine of openness, not in
the long shadows of industry influence [13]. This sort of
disentanglement is one step towards a more healthy relationship
between doctors and drug companies.
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